Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
5.97
-0.03 (-0.50%)
Jul 11, 2025, 4:00 PM - Market closed
Immatics Employees
As of December 31, 2024, Immatics had 682 total employees, including 554 full-time and 128 part-time employees. The number of employees increased by 147 or 27.48% compared to the previous year.
Employees
682
Change (1Y)
147
Growth (1Y)
27.48%
Revenue / Employee
$228,449
Profits / Employee
-$35,495
Market Cap
725.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
IMTX News
- 6 weeks ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire
- 2 months ago - Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Immatics N.V.: Trading Below Cash, But Not Without Reason - Seeking Alpha
- 3 months ago - Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 8 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 8 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire
- 9 months ago - Immatics: A Promising TCR Pipeline - Seeking Alpha